Glycated and carbamylated albumin are more "nephrotoxic" than unmodified albumin in the amphibian kidney

American Journal of Physiology - Renal Physiology

Volumn 301, Issue 3, 2011, Pages

  Gross, M L ^a   Piecha, G ^a,d   Bierhaus, A ^d   Hanke, W ^b   Henle, T ^c   Schirmacher, P ^a   Ritz, E ^d  

^a Institute of Pathology   (Germany)

^b UNIVERSITY OF KARLSRUHE   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Albuminuria; Carbamylation; Diabetes; Diabetic nephropathy; Glycation; Interstitial fibrosis; NF B

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALBUMIN; ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; BOVINE SERUM ALBUMIN; CARBAMYLATED ALBUMIN; CLUSTERIN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; GLYCOSYLATED ALBUMIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUBULIN; UNCLASSIFIED DRUG;

AMBYSTOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBAMOYLATION; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GLYCATION; HISTOCHEMISTRY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KIDNEY; KIDNEY FIBROSIS; KIDNEY TUBULE DAMAGE; KIDNEY TUBULE FIBROSIS; LIPID DEGRADATION; LIPID OXIDATION; MALE; MICROSCOPY; NEPHRON; NEPHROTOXICITY; NONHUMAN; PERITONEAL CAVITY; PERITONEUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 80052412857     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00342.2010     Document Type: Article

References (39)

1. Ahmed MU, Thorpe SR, Baynes JW. Identification of N epsiloncarboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 261: 4889-4894, 1986.
2. Amann K, Kronenberg G, Gehlen F, Wessels S, Orth S, Munter K, Ehmke H, Mall G, Ritz E. Cardiac remodelling in experimental renal failure-an immunohistochemical study. Nephrol Dial Transplant 13: 1958-1966, 1998.
3. Anders HJ, Vielhauer V, Frink M, Linde Y, Cohen CD, Blattner SM, Kretzler M, Strutz F, Mack M, Grone HJ, Onuffer J, Horuk R, Nelson PJ, Schlondorff D. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 109: 251-259, 2002.
4. Eddy A. Role of cellular infiltrates in response to proteinuria. Am J Kidney Dis 37: S25-D29, 2001.
5. Eddy AA. Interstitial nephritis induced by protein-overload proteinuria. Am J Pathol 135: 719-733, 1989.
6. Gassner KM, Tassava RA. Abnormal limb regeneration in the short-toes mutant of the axolotl, Ambystoma mexicanum: studies of age, level of amputation, and extracellular matrix. J Exp Zool 279: 571-578, 1997.
7. Gerard P, Cordier R. Sur l'interpretation des alterations morphologiques characteristiques observees dans le rein au corps de la nephrose lipoidique. CR de l'Assaoc des Anat 29: 225-232, 1934.
8. Grandaliano G, Gesualdo L, Ranieri E, Monno R, Montinaro V, Marra F, Schena FP. Monocyte chemotactic peptide-1 expression in acute and chronic human nephritides: a pathogenetic role in interstitial monocytes recruitment. J Am Soc Nephrol 7: 906-913, 1996.
9. Grone HJ, Weber C, Weber KS, Grone EF, Rabelink T, Klier CM, Wells TN, Proudfood AE, Schlondorff D, Nelson PJ. Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. FASEB J 13: 1371-1383, 1999.
10. Gross ML, Hanke W, Koch A, Ziebart H, Amann K, Ritz E. Intraperitoneal protein injection in the axolotl: the amphibian kidney as a novel model to study tubulointerstitial activation. Kidney Int 62: 51-59, 2002.
11. Henle T, Deppisch R, Beck W, Hergesell O, Hansch GM, Ritz E. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol Dial Transplant 14: 1968-1975, 1999.
12. Henle TSU, Klostermeyer H. Detection and quantification of pentosidine in food. Z Lebensm Unters Forsch 204: 95-98, 1997.
13. Janssens PA, Grigg JA. Binding of adrenergic ligands to liver plasma membrane preparations from the axolotl, Ambystoma mexicanum; the toad, Xenopus laevis; and the Australian lungfish, Neoceratodus forsteri. Gen Comp Endocrinol 71: 524-530, 1988.
14. Knecht A, Fine LG, Kleinman KS, Rodemann HP, Muller GA, Woo DD, Norman JT. Fibroblasts of rabbit kidney in culture. II. Paracrine stimulation of papillary fibroblasts by PDGF. Am J Physiol Renal Fluid Electrolyte Physiol 261: F292-F299, 1991.
15. Li JH, Wang W, Huang XR, Oldfield M, Schmidt AM, Cooper ME, Lan HY. Advanced glycation end products induce tubular epithelialmyofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol 164: 1389-1397, 2004.
16. Mezzano S, Droguett A, Burgos ME, Ardiles LG, Flores CA, Aros CA, Caorsi I, Vio CP, Ruiz-Ortega M, Egido J. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl S64-S70, 2003.
17. Mogensen CE. Urinary albumin excretion in diabetes. Lancet 2: 601-602, 1971.
18. Nangaku M, Pippin J, Couser WG. C6 mediates chronic progression of tubulointerstitial damage in rats with remnant kidneys. J Am Soc Nephrol 13: 928-936, 2002.
19. Nath KA. The tubulointerstitium in progressive renal disease. Kidney Int 54: 992-994, 1998.
20. Nieuwkoop PD, Bjorklund NK, Gordon R. Surface contraction and expansion waves correlated with differentiation in axolotl embryos. II. In contrast to urodeles, the anuran Xenopus laevis does not show furrowing surface contraction waves. Int J Dev Biol 40: 661-664, 1996.
21. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, Atkins RC, Osicka T, Jerums G, Cooper ME. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 108: 1853-1863, 2001.
22. Parving HH. Effects of ACE inhibitors on renal function in incipient and overt diabetic nephropathy. J Diabetes Complications 10: 133-135, 1996.
23. Prodjosudjadi W, Gerritsma JS, Klar-Mohamad N, Gerritsen AF, Bruijn JA, Daha MR, van Es LA. Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int 48: 1477-1486, 1995.
24. Remuzzi G. Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury. Curr Opin Nephrol Hypertens 4: 339-342, 1995.
25. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998.
26. Rodriguez-Ayala E, Anderstam B, Suliman ME, Seeberger A, Heimburger O, Lindholm B, Stenvinkel P. Enhanced RAGE-mediated NFkappaB stimulation in inflamed hemodialysis patients. Atherosclerosis 180: 333-340, 2005.
27. Schreiner GF. Renal toxicity of albumin and other lipoproteins. Curr Opin Nephrol Hypertens 4: 369-373, 1995.
28. Strutz F, Neilson EG. New insights into mechanisms of fibrosis in immune renal injury. Springer Semin Immunopathol 24: 459-476, 2003.
29. Thomas ME, Brunskill NJ, Harris KP, Bailey E, Pringle JH, Furness PN, Walls J. Proteinuria induces tubular cell turnover: a potential mechanism for tubular atrophy. Kidney Int 55: 890-898, 1999.
30. van Timmeren MM, Gross ML, Hanke W, Klok PA, van Goor H, Stegeman CA, Bakker SJ. Oleic acid loading does not add to the nephrotoxic effect of albumin in an amphibian and chronic rat model of kidney injury. Nephrol Dial Transplant 23: 3814-3823, 2008.
31. Wahab NA, Mason RM. A critical look at growth factors and epithelialto-mesenchymal transition in the adult kidney. Interrelationships between growth factors that regulate EMT in the adult kidney. Nephron Exp Nephrol 104: e129-e134, 2006.
32. Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DC. Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 8: 1537-1545, 1997.
33. Weisgraber KH, Innerarity TL, Mahley RW. Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J Biol Chem 253: 9053-9062, 1978.
34. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67: 799-812, 2005.
35. Zandi-Nejad K, Eddy AA, Glassock RJ, Brenner BM. Why is proteinuria an ominous biomarker of progressive kidney disease? Kidney Int Suppl: S76-S89, 2004.
36. Zeisberg M, Bonner G, Maeshima Y, Colorado P, Muller GA, Strutz F, Kalluri R. Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol 159: 1313-1321, 2001.
37. Zoja C, Benigni A, Remuzzi G. Cellular responses to protein overload: key event in renal disease progression. Curr Opin Nephrol Hypertens 13: 31-37, 2004.
38. Zoja C, Benigni A, Remuzzi G. Protein overload activates proximal tubular cells to release vasoactive and inflammatory mediators. Exp Nephrol 7: 420-428, 1999.
39. Zoja C, Morigi M, Figliuzzi M, Bruzzi I, Oldroyd S, Benigni A, Ronco P, Remuzzi G. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 26: 934-941, 1995.